spacer
home > pmps > winter 2018 > uncommon codes
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Uncommon Codes

With deadlines approaching in Europe, the US, and other countries, pharmaceutical companies and CMOs on both sides of the Atlantic are scrambling to implement viable serialisation solutions to comply with regulatory requirements, such as the Falsified Medicines Directive and the Drug Supply Chain Security Act.

While a lot of time and resources have already been expended on line-site implementation, connecting the dots with sufficient infrastructure – both at the enterprise level and along the ensuing supply chain – is now critical. Today, serialisation compliance clearly affects aspects of a business far beyond the production line. From manufacturing through to the point of dispensation, great demands exist to exchange information between trading partners and stakeholders to address both regulatory requirements and business challenges.

Ensuring Unique Numbers


The life of a serialised product begins with the generation of a unique serial number. When producing medicines for markets where serial numbers are not created and managed by authorities, the need for generating and exchanging serial numbers depends on a pharma company’s size, structure, and business strategy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pavel Lotkov is Product Director for Adents. Formerly with Eli Lilly, Pavel has more than 16 years of information technology experience and possesses a deep understanding of business operations at large pharma companies. As solution implementation and adoption lead, Pavel focused on regulatory requirements and business process analysis, risk impact assessment, system validation, and solution provider management. Pavel was instrumental in providing tactical and strategic support to Lilly’s functional areas impacted by serialisation.
spacer
Pavel Lotkov
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement